AtriCure (NASDAQ:ATRC) PT Lowered to $40.00 at Needham & Com

AtriCure (NASDAQ:ATRC – Get Free Report) had its price objective dropped by analysts at Needham & Company LLC from $46.00 to $40.00 in a report released on Thursday, Benzinga reports. The firm currently has a “buy” rating on the medical device company’s stock. Needham & Company LLC’s price objective points to a potential upside of […]

Related Keywords

United States , Karls Dahlquist , Zurcher Kantonalbank Zurich Cantonalbank , Stifel Nicolaus , Nasdaq , Securities Exchange Commission , Needham Company , Atricure Inc , Mirae Asset Global Investments Co , Sg Americas Securities , Atricure Company Profile , Assetmark Inc , Get Free Report , Cure Stock Down , Exchange Commission , Kantonalbank Zurich Cantonalbank , Asset Global Investments , Isolator Synergy Clamps , Atricure Daily , Atricure , Nasdaq Atrc , Atrc , Medical , 04963c20 , Lower Price Target , Needham Company Llc ,